Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
09/2003
09/25/2003WO2003078576A2 Vector for transfection of eukaryotic cells
09/25/2003WO2003078568A2 Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor
09/25/2003WO2003078469A1 Anti-human hepatoma monoclonal antibody hab18 light/heavy chain variable region gene, and use thereof
09/25/2003WO2003078462A2 Cells transfected with a nucleotide sequence encoding glp-1 and secreting insulin in a glucose-dependent manner
09/25/2003WO2003078383A1 Novel positively charged lipids and liposomes comprising the positively charged lipids
09/25/2003WO2003077871A2 Method of diagnosis and treatment of breast lesions
09/25/2003WO2003077863A2 Method for overexpression of zwitterionic polysaccharides
09/25/2003WO2003077859A2 Method of inducing an enhanced immune response against hiv
09/25/2003WO2003077852A2 CARTILAGE REGENERATION USING CHONDROCYTE AND TGF-β
09/25/2003WO2003077834A2 Central airway administration for systemic delivery of therapeutics
09/25/2003WO2003077796A2 Ophthalmic solutions for delivery of expression vectors
09/25/2003WO2003060101A3 Gene delivery system and methods of use
09/25/2003WO2003042411A3 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease
09/25/2003WO2003042246A3 Inhibitors of the notch signalling pathway for use in the treatment of cancer
09/25/2003WO2003042245B1 Growth hormone variations in humans and their uses
09/25/2003WO2003035879A3 Promoters to control cell differentiation
09/25/2003WO2003033519A3 Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo
09/25/2003WO2003022988A3 Adipose-derived stem cells and lattices
09/25/2003WO2003018064A3 Lipophilic drug compositions
09/25/2003WO2003016521A3 Aav vector packaging plasmid for producing wtaav particles or pseudotyped aav particles without helper viruses, by means of a single transfection
09/25/2003WO2003013594A3 Modulation of antibody formation in mammals, applicability in gene therapy and animal model generation
09/25/2003WO2003013577A3 Use of il-18 inhibitors in hypersensitivity disorders
09/25/2003WO2003000907A3 Improved transfection of eukaryotic cells with linear polynucleotides by electroporation
09/25/2003WO2002100324A3 Compositions and methods for the repair and construction of bone and other tissue
09/25/2003WO2002099116A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
09/25/2003WO2002097059A9 Chromosome-based platforms
09/25/2003WO2002088370A3 Autogene nucleic acids encoding a secretable rna polymerase
09/25/2003WO2002083850A8 Vascular endothelial growth factor 2
09/25/2003WO2002081705A3 Regulation of human gnat acetyltransferase-like protein
09/25/2003WO2002077263A3 Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
09/25/2003WO2002076482A3 USE OF IKK-β INHIBITORS AND METHOD FOR DISCOVERY OF SAID INHIBITORS
09/25/2003WO2002064612A9 Human g-protein chemokine receptor (ccr5) hdgnr10
09/25/2003WO2002063004A3 G-protein coupled receptors
09/25/2003WO2002046419A3 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
09/25/2003WO2002020754A3 Molecules for diagnostics and therapeutics
09/25/2003WO2002014368A3 Proteins and nucleic acids encoding the same
09/25/2003WO2002012469A3 A human adenylate kinase family member and uses therefor
09/25/2003WO2002010378A3 Antisense modulation of ptp1b expression
09/25/2003WO2002010364A3 Methods for enhancing targeted gene alteration using oligonucleotides
09/25/2003US20030182681 Introducing into a eukaryotic cell a cytotoxic Pseudomonas protein to cause the cell death; disease resistance plant
09/25/2003US20030181706 Inflammation-associated polynucleotides
09/25/2003US20030181692 207 human secreted proteins
09/25/2003US20030181689 Percarboxylated polysaccharides, and a process for their preparation
09/25/2003US20030181661 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
09/25/2003US20030181660 Low-density lipoproteins (LDL); diabetes; autoimmune disorders
09/25/2003US20030181659 Thrombopoietin receptor modulating peptide
09/25/2003US20030181658 Exhibit protease activity as a single chain or as an activated two chain form; use of polypeptides to identify compounds that modulate the protease activity thereof and as tumor markers
09/25/2003US20030181518 Compositions and methods for treating cystic fibrosis
09/25/2003US20030181405 Interferon alpha plasmids and delivery systems, and methods of making and using the same
09/25/2003US20030181404 Inhibiting cell growth with a genetic engineered kinase
09/25/2003US20030181403 A gene therapy for cancers, comprising a cancer suppressing gene; genetic engineering, duplicated gene, cloned gene
09/25/2003US20030181381 Factor X analogues having a modified protease cleavage site
09/25/2003US20030181379 Novel fibroblast growth factor (FGF23) and methods for use
09/25/2003US20030181377 Inhibition of VEGF receptor signaling reverses tumor resistance to radiotherapy
09/25/2003US20030181369 Method of modulating glycosylation pathways
09/25/2003US20030181367 Membrane translocation peptides, compositions comprising them, chimeric molecules comprising them, and methods of using them to achieve transmembrane transport of various agents.
09/25/2003US20030181364 Genes and methods for the screening of therapeutics useful for treating impaired glucose tolerance conditions, as well as diagnostics and therapeutic compositions for identifying or treating such conditions.
09/25/2003US20030181362 Receptor
09/25/2003US20030180953 Gene disruption methodologies for drug target discovery
09/25/2003US20030180936 Method for the purification, production and formulation of oncolytic adenoviruses
09/25/2003US20030180935 ICE/CED-3 like protease designated FMH-1
09/25/2003US20030180934 Plasminogen-like polynucleotides, polypeptides, and antibodies
09/25/2003US20030180931 Cellubrevin homologs
09/25/2003US20030180930 Isolated nucleic acid sequences, cell cultures, encoded polypeptide, antigen-binding antibodies; treating or preventing aberrant disorder, antiproliferative agents, promoting cell differentiation, cancer, liver disorders
09/25/2003US20030180883 Human tumor necrosis factor receptor TR10
09/25/2003US20030180880 Chromosome 1 gene and gene products related to alzheimer's disease
09/25/2003US20030180877 Gene therapy; drug screening
09/25/2003US20030180818 Isolated nucleic acid molecules encoding human peptidoglycan recognition protein-related proteins, referred to PGRP-K (keratinocytes), PGRP-W (wound healing) and PGRP-C (chondrosarcoma)
09/25/2003US20030180817 Determining levels of a colon specific gene in the cells, or bodily fluids in a patient, comparing determined levels of CSG with levels of CSG in cells from normal human control, wherein a change in level of CSG indicates presence of cancer
09/25/2003US20030180799 Antibodies against plasma cells
09/25/2003US20030180785 Polynucleotide molecules encoding Neospora proteins
09/25/2003US20030180778 UDP-N-acetylglucosamine: galactose-beta1,3-N-acetylgalactosamine-alpha-R/ (GlcNAc to GalNAc) beta1,6-N-acetylglucosaminyltransferase, C2GnT3
09/25/2003US20030180762 Mild enrichment of foetal cells from peripheral blood and use thereof
09/25/2003US20030180759 Antigen derived from the gp160 env precursor protein (glycoprotein120 envelop protein)of a HIV-1 group O strain contains an amino acid sequence characterized by the fact that it reacts with antibodies raised against such antigen
09/25/2003US20030180755 Pharmaceutical compositions in particulate form
09/25/2003US20030180753 Full length human hcn1ih channel subunit and variants
09/25/2003US20030180752 Type 2 cytokine receptor and nucleic acids encoding same
09/25/2003US20030180747 Pancreatic cancer diagnosis and therapies
09/25/2003US20030180738 Use of a specific nucleic acid molecule or probe in combination with a reverse transcription polymerase chain reaction
09/25/2003US20030180736 Methods for the early diagnosis of ovarian cancer
09/25/2003US20030180734 Peptide nucleic acids
09/25/2003US20030180719 Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis C virus infections
09/25/2003US20030180707 Recombinant expression construct encoding a reporter gene operably linked to a promoter from a gene the expression of which is induced by a retinoid, wherein the promoter does not contain a retinoic acid response elements site
09/25/2003US20030180327 Veterinary medicine; induce immunology response
09/25/2003US20030180326 Methods and compositions for impairing multiplication of HIV-1
09/25/2003US20030180317 Diagnosis ear infections in children
09/25/2003US20030180315 Novel proteins in enteroaggregative escherichia coli (EAEC) useful for diagnosis and therapy of EAEC infections
09/25/2003US20030180302 Genetic engineering
09/25/2003US20030180301 Prevention organ rejection; induction immunology response; reduce fibrosis
09/25/2003US20030180300 Collagen biosynthesis; controlling cell differentiation, cell proliferation
09/25/2003US20030180294 Administering vascular endothelial growth factor receptor inhibitor; supression lymphangiogenesis
09/25/2003US20030180267 Genetic engineering; controlling gene expression in situ
09/25/2003US20030180266 Methods of expressing LIM mineralization protein in non-osseous cells
09/25/2003US20030180265 Modulating angiogenesis
09/25/2003US20030180264 Using catheter or stent; in situ tissue transfer
09/25/2003US20030180261 Vaccines; cancer therapy; immobilization of virus; supplying tumor
09/25/2003US20030180258 Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells
09/25/2003CA2479246A1 Method for overexpression of zwitterionic polysaccharides
09/25/2003CA2479212A1 Central airway administration for systemic delivery of therapeutics
09/25/2003CA2479187A1 Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
1 ... 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 ... 870